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Summary
Polo kinase is activated as cells enter mitosis and
plays a central role in coordinating diverse mitotic
events, yet the mechanisms leading to activation
of Polo kinase are poorly understood [1]. Work in
Xenopus meiotic cell cycles has suggested that Polo
kinase functions in a pathway that helps trigger activa-
tion of Cdk1 [2–5]. However, studies in other organ-
isms have suggested that activation of Polo kinase is
dependent upon Cdk1 and therefore occurs down-
stream of Cdk1 activation [6–8]. In this study, we have
investigated the role of Cdk1 in the activation of bud-
ding yeast Polo kinase. The budding yeast homologs
of Cdk1 and Polo kinase are referred to as Cdc28 and
Cdc5. We show that signaling from Cdc28 is required
to maintain Cdc5 activity in vivo. Furthermore, purified
Cdc28 associated with the mitotic cyclin Clb2 is suffi-
cient to activate purified Cdc5 in vitro. A single Cdc28
consensus phosphorylation site found at threonine
242 in the activation loop segment of Cdc5 is required
for Cdc5 function in vivo and for kinase activity in vitro,
whereas four other Cdc28 consensus sites are dis-
pensable. Analysis of Cdc5 phosphorylation by mass
spectrometry indicates that threonine 242 is phos-
phorylated in vivo. These results suggest that Cdc28
activates Cdc5 via phosphorylation of threonine 242.
Results and Discussion
To test whether Cdc28 is required for Cdc5 activity, we
utilized an analog-sensitive allele of Cdc28 (Cdc28-as1)
that can be rapidly and specifically inhibited in vivo by
addition of the adenine analog 1NM-PP1 [9]. Cells carry-
ing the Cdc28-as1 allele were incubated in the presence
of a microtubule-destabilizing drug to arrest cells in mi-
tosis, when Cdc5 is most active [10, 11]. The arrested
cells were then treated with 1NM-PP1 and samples
were taken every 5 min for 15 min. Cdc5 was immuno-
precipitated from the samples and tested for its ability
to phosphorylate casein. Treatment of Cdc28-as1 cells
with 1NM-PP1 caused a rapid 5-fold decrease in Cdc5
activity (Figure 1A). Treatment of wild-type cells with
the same concentration of 1NM-PP1 had no effect
(Figure 1B). These results demonstrate that Cdc28 activ-
*Correspondence: kellogg@biology.ucsc.eduity is required for the maintenance of Cdc5 activity in
cells arrested in mitosis.
To examine the effects of Cdc28 inhibition on Cdc5
activity during a normal mitosis, we synchronized
Cdc28-as1 cells in G1 with mating pheromone, released
them synchronously into the cell cycle, and added 1NM-
PP1 as the cells entered mitosis at 75 min. Samples were
taken 7.5 min after 1NM-PP1 addition and Cdc5 kinase
activity was assayed. After 7.5 min of Cdc28 inhibition,
Cdc5 kinase activity was reduced 6-fold relative to a
mock-treated control (Figure 1C, compare lanes 2 and
3). Note that the cells were still undergoing entry into mi-
tosis and Cdc5 activity was therefore rising at the time of
1NM-PP1 addition. As a result, the mock-treated control
has greater Cdc5 kinase activity than the initial time
point. These results demonstrate that Cdc28 activity is
required for Cdc5 activity during a normal mitosis.
We next tested whether Cdc28 can directly activate
Cdc5. Since Cdc28 associates with the mitotic cyclin
Clb2 to promote entry into mitosis, we tested whether
purified Cdc28/Clb2 complexes can activate purified
Cdc5 in vitro. An inactive form of Cdc5 was created by
immunoprecipitating Cdc5 from cells arrested in mito-
sis, followed by treatment with lambda phosphatase.
The phosphatase treatment eliminated Cdc5-associ-
ated kinase activity, and addition of purified Cdc28/
Clb2 complexes in the presence of ATP restored Cdc5
kinase activity to untreated levels (Figure 1D, lanes 1,
2, 3, and 6). A systematic screen for substrates of
Clb2/Cdc28 complexes independently identified Cdc5
as a potential target of Cdc28/Clb2 [12].
Cdc5 has one strict Cdc28-consensus site (S/T-P-X-
K/R) and four minimal sites (S/T-P). We therefore made
single mutants that change each of these residues to
a nonphosphorylatable alanine and assayed their ability
to rescue a loss of CDC5 function. The mutants were ex-
pressed from the endogenousCDC5promoter in a strain
that is dependent upon a single copy of CDC5 ex-
pressed from the GAL1 promoter. Four of the mutants
were able to support viability when cells were grown in
the presence of dextrose to turn off expression of wild-
type CDC5; however, cells carrying the cdc5-T242A al-
lele as their sole source of Cdc5 were inviable and ex-
hibited a late mitotic arrest similar to the arrest caused
by temperature-sensitive alleles of CDC5 (Figure 2A
and data not shown).
Threonine 242 is conserved in all Polo kinases and is
located within a region of the kinase domain that com-
prises an ‘‘activation loop’’ in many kinases (Figure 2B)
[13]. Phosphorylation of residues within this activation
loop is often required for activation of kinases. We there-
fore asked whether the cdc5-T242A mutation eliminated
kinase activity in vitro. As shown in Figure 2C, the cdc5-
T242A allele eliminated Cdc5 kinase activity to the same
extent as a kinase-dead cdc5-K110A allele. Threonine
242 is therefore required for Cdc5 function in vivo and
for kinase activity in vitro. We next generated a mutant
version of CDC5 in which all four of the nonessential
consensus sites were mutated to alanine (cdc5-4A).
We found that Cdc5-4A was activated by Cdc28/Clb2
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2034Figure 1. Cdc28 Is Required for Cdc5 Activity
In Vivo and Can Activate Cdc5 In Vitro
(A) cdc28-as1 CDC5-3XHA cells were ar-
rested in mitosis with nocodazole, 25 mM
1NM-PP1 was added, and time points were
taken every 5 min. Cdc5-3XHA was immuno-
precipitated and kinase activity was assayed
by phosphorylation of casein (bottom). Levels
of immunoprecipitated Cdc5-3XHA were
monitored by Western blotting (top).
(B) A control showing that treatment of wild-
type cells with 1NM-PP1 had no effect on
Cdc5-3XHA activity. Wild-type Cdc28 cells
were arrested in mitosis with nocodazole,
25 mM 1NM-PP1 was added, and a sample
was taken 15 min later. Cdc5-3XHA was im-
munoprecipitated and kinase activity was
assayed by phosphorylation of casein.
(C) Cdc28 is required for Cdc5 activity in a nor-
mal cell cycle. cdc28-as1 cells were arrested
in G1 with a factor and released synchro-
nously into the cell cycle. An initial time point
was taken at 75 min as the cells were entering
mitosis (lane 1). Identical aliquots of cells
were then treated with 25 mM 1NM-PP1 or
with DMSO and samples were taken after
7.5 min. Cdc5-3XHA was immunoprecipi-
tated from each sample and kinase activity
was assayed by phosphorylation of casein
(bottom). The lane marked ‘‘Control’’ corre-
sponds to the sample mock-treated with
DMSO.
(D) Activation of Cdc5 by Cdc28/Clb2 in vitro.
Wild-type or mutant versions of Cdc5-3XHA
were immunoprecipitated from cells arrested
in mitosis and incubated in the presence or
absence of lambda phosphatase. After wash-
ing away the phosphatase, Cdc5-3XHA was
incubated in the presence or absence of
Cdc28/Clb2 and ATP. Kinase assays were
then performed on each sample using casein
as a substrate. Cdc5-3XHA protein levels
were monitored by Western blotting (top),
and kinase activity was assayed by phos-
phorylation of casein (bottom).to levels similar to wild-type Cdc5 (Figure 1D, compare
lanes 3 and 5). The cdc5-4A allele was also able to res-
cue the cdc5-1 temperature-sensitive allele when ex-
pressed from the GAL1 promoter (data not shown). In
contrast, Cdc5-T242A could not be reactivated by
Cdc28 after treatment with phosphatase (Figure 1D,
lane 4). These results suggest that Cdc28 can stimulate
Cdc5 kinase activity through phosphorylation of threo-
nine 242.
To determine whether T242 is phosphorylated in vivo
and to identify other phosphorylated residues, we used
immunoaffinity chromatography to isolate Cdc5 from
cells arrested in mitosis and mapped phosphorylation
sites by mass spectrometry. This analysis identified
ten phosphorylation sites, including T242 (Figure 3).
The analysis also revealed that a neighboring threonine
is phosphorylated (T238). Previous work reported that
the threonine corresponding to T238 is also phosphory-
lated in Xenopus and mammalian cells; however, the
function of this phosphorylation is controversial. In one
case, it was found that mutation of the correspondingthreonine to an alanine caused a slight reduction in
Polo kinase activity in vitro [14]. A second study found
that changing the threonine to a valine caused a com-
plete loss of kinase activity [15]. We mutated T238 to
an alanine but observed no phenotype, which suggests
that T238 phosphorylation is not strictly required for
Cdc5 activity in vivo. We also individually mutated the
other phosphorylation sites identified by mass spec-
trometry and assayed their ability to support viability in
the absence of wild-type Cdc5 (not shown). Of the nine
phosphorylation site mutants that we tested, only threo-
nine 242 was required for Cdc5 function. We have not
yet tested whether S73 is required for viability.
Taken together, our results suggest that Cdc28 plays
an important and direct role in activation of Cdc5 kinase
activity. The finding that Cdc5 is downstream of Cdc28
in budding yeast is consistent with the fact that temper-
ature-sensitive cdc5 mutants arrest in late mitosis [10,
16]. To further test whether Cdc5 might act upstream
of Cdc28, we used mitotic spindle assembly as a marker
for entry into mitosis and determined whether the cdc5-1
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2035Figure 2. Threonine 242 Is Conserved in
Members of the Polo-like Kinase Family and
Is Required for Cdc5 Kinase Activity In Vitro
(A) Cdc28-consensus site mutants were
tested for their ability to support growth in
the absence of wild-type Cdc5. Cells depen-
dent upon GAL1-CDC5 were transformed
with CEN plasmids carrying the indicated
Cdc28 consensus site mutants and tested
for growth on media containing galactose or
dextrose.
(B) An alignment of activation segment loops
in diverse Polo kinases showing that T242 is
conserved. Threonine 242 in Cdc5 is indi-
cated by an asterisk.
(C) Wild-type CDC5, cdc5-K110A, and cdc5-
T242A were expressed as 3XHA fusion pro-
teins from the GAL1 promoter in cells ar-
rested in mitosis with benomyl. The kinases
were immunoprecipitated and assayed for ki-
nase activity by phosphorylation of casein
(bottom), and Cdc5-3XHA protein levels in
the immunoprecipitates were monitored by
Western blotting (top).temperature-sensitive allele shows delayed entry into
mitosis. We observed no delay, which further suggests
that Cdc5 does not act upstream of mitotic Cdc28 in
budding yeast (data not shown). Previous work has
shown that Cdc5 activity is exactly correlated with
Clb2/Cdc28 activity in vivo, which further supports the
idea that Clb2/Cdc28 activates Cdc5 [10]. Our results
suggest that phosphorylation of T242 provides the major
contribution to activation of Cdc5; however, we cannot
rule out the possibility that additional phosphorylations
contribute to Cdc5 activation in vivo.
In contrast to our results in budding yeast, previous
studies carried out in Xenopus meiotic cells suggested
that Polo kinase functions upstream of Cdk1 as a regula-
tor of the Cdc25 phosphatase. In these experiments, it
was found that Polo kinase can bind, phosphorylate,
and activate Cdc25, which triggers activation of Cdk1
[4, 5]. In addition, immunodepletion of Polo kinase
blocks activation of Cdc25 and entry into mitosis [4].
However, work in other cell types suggested that Polo
kinases may not act upstream of Cdk1. For example, in-
hibition of Polo kinase in mammalian cells with siRNA
had no effect on entry into mitosis or activation of
Cdk1 [17, 18]. Similarly, experiments in fission yeast
have suggested that Polo kinase activation is down-
stream of Cdk1 [6]. A role for Polo kinases upstream of
Cdk1 may be unique to Xenopus meiotic cells. It is also
possible that Polo kinases act both upstream and down-
stream of Cdk1 and that the relative importance of the
upstream role of Polo kinases varies between cell types.
Further work will be necessary to determine the mecha-
nisms that ensure proper spatial and temporal regula-
tion of Cdc5/Polo kinase activity during mitosis.Experimental Procedures
Yeast Plasmid and Strain Construction
The CDC5 gene was amplified from yeast genomic DNA and cloned
into the EcoR1 and BamH1 sites in Ycplac22 to generate pEM110
(oligos GCGGAATTCCTGAGAAAGTAAATCCAATTC and 30- GCGG
GATCCAACGCTATATGAGAACTATTG). An integrating vector con-
taining Cdc5-3XHA under the control of the GAL1 promoter was
generated by cloning CDC5 into the BamH1 and Eag1 sites in
pSH32 to produce pEM120 (oligos 50-GCGGGATCCATGTCGTTGG
GTCCTCTTAAA and GCGCGGCCGATCTACGGTAACAATTGTGG).
This plasmid was cut with Stu1 to integrate GAL1-CDC5-3XHA at
the URA3 locus. The following plasmids carrying mutant versions
of CDC5 were created by mutagenesis of pEM120: pEM121
(GAL1-CDC5K110A-3XHA), pEM122 (GAL1-CDC5T242A-3XHA), and
pEM126 (GAL1-CDC5-4A-3XHA). The following plasmids were gen-
erated by mutagenesis of pEM110: pEM130 (encoding Cdc5T23A),
pEM131 (Cdc5T70A), pEM132 (Cdc5T242A), pEM133 (Cdc5S419A),
pEM134 (Cdc5S657A), pEM136 (Cdc5S2A), pEM137 (Cdc5S18A),
pEM138 (Cdc5T29A), pEM139 (Cdc5S119A), pEM140 (Cdc5T238A),
pEM141 (Cdc5S417A), and pEM142 (Cdc5T423A).
All strains were created in the W303 background (leu2-3,112 ura3-
52 can1-100 ade2-1 his3-11 trp1-11). The additional features of the
strains used in this study are listed: EM42: CDC5-3XHA::HIS5,
Cdc28-as1; EM54: CDC5-3XHA::HIS5; EM55: GAL1-CDC5-3XHA::
URA3 (pEM120); EM56: GAL1-CDC5-K110A-3XHA::URA3
(pEM121); EM57: GAL1-CDC5-T242A-3XHA::URA3 (pEM122);
EM58: GAL1-CDC5-4A-3XHA::URA3 (pEM126); EM61: GAL1-
CDC5::URA3, CDC5T23A::TRP1 (pEM130); EM62:GAL1-CDC5::URA3,
CDC5T70A::TRP1 (pEM131); EM63: GAL1-CDC5::URA3, CDC5T
242A::TRP1 (pEM132); EM64: GAL1-CDC5::URA3, CDC5S419A::TRP1
(pEM133); EM65: GAL1-CDC5::URA3, CDC5S657A::TRP1 (pEM134);
EM66: GAL1-CDC5::URA3, CDC5S2A::TRP1 (pEM136); EM67:
GAL1-CDC5::URA3, CDC5S18A::TRP1 (pEM137); EM68: GAL1-
CDC5::URA3, CDC5T29A::TRP1 (pEM138); EM69:GAL1-CDC5::URA3,
CDC5S119A::TRP1 (pEM139); EM70: GAL1-CDC5::URA3, CDC5T
238A::TRP1 (pEM140); EM71: GAL1-CDC5::URA3, CDC5S417A::TRP1
(pEM141); EM72: GAL1-CDC5::URA3, CDC5T423A::TRP1 (pEM142).
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Cdc5-3XHA was expressed from the endogenous promoter and immunoprecipitated from cells arrested in mitosis. Phosphorylation sites were
mapped by mass spectrometry.
(A) A table showing phosphorylation sites mapped by mass spectrometry.
(B) MS/MS spectrum of the doubly charged diphosphopeptide KYTICGTPNYIAPEVLMGK (236–254, m/z) from Cdc5. The threonine residues
T238 and T242 were identified to be phosphorylated as indicated by asterisks. Predicted m/z values for the b- and y-type ions are listed and
ions observed in the MS/MS spectrum are in bold font.Cell Cycle Arrests, In Vitro Kinase Assays, Western Blotting, and
Treatment with Phosphatase and 1NM-PP1
To examine the effects of Cdc28 inhibition on Cdc5 kinase activity
(Figures 1A and 1B), strains EM42 and EM54 were grown overnight
in YPD to an optical density of 0.5 and arrested in mitosis by incuba-
tion in YPD containing 30 mg/ml benomyl for 2 hr, followed by treat-
ment with 25 mm 1NM-PP1. The cells from 25 ml of culture were used
for each kinase assay. Extracts for kinase assays were made as de-
scribed previously [19]. Cdc5-3XHA immunoprecipitations for ki-
nase assays were carried out in the presence of a high salt buffer
to remove associated proteins (IP buffer: 50 mM HEPES-KOH [pH
7.6], 1 M KCl, 50 mM b-glycerophosphate, 50 mM NaF, 1 mM
EGTA, 1 mM MgCl2, 0.15% Tween-20, 10% glycerol, 1 mM PMSF).
All immunoprecipitations were performed as described previously
via a polyclonal HA antibody [19]. Kinase reactions were performedby incubating immunoprecipitated Cdc5-3XHA in 20 ml kinase assay
buffer (50 mM HEPES-KOH [pH 7.6], 1 mM EGTA, 2 mM MgCl2, 0.1%
Tween-20, 10% glycerol, 1 mM dithiothreitol) supplemented with
0.25 mM ATP, 0.1 ml [g-32P]ATP and 5 mg casein. Kinase reactions
were incubated for 30 min at 30ºC. Reactions were terminated
by the addition of 43 sample buffer and run on 11% SDS-PAGE
gels [20].
For reactivation of phosphatase-treated Cdc5 by Cdc28/Clb2
(Figure 1C), strains containing wild-type or mutant versions of
Cdc5-3XHA under the control of the galactose promoter (strains
EM55, EM56, EM57, EM58) were grown overnight in YEP + 2% raffi-
nose to exponential phase. Galactose was then added to 2% and
cells were incubated for 2 hr at room temperature prior to the addi-
tion of nocodazole to 20 mg/ml. Immunoprecipitated Cdc5-3XHA
was treated with 1.5 ml l phosphatase (New England Biolabs) for
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with kinase assay buffer. After the final wash, 20 ml kinase buffer sup-
plemented with 1 mM ATP was added along withw.25 ng of purified
Cdc28/Clb2-3XHA. The reaction was incubated for 30 min at 30ºC
and was then washed three times with IP buffer; Cdc5 kinase activity
was then assayed as described above. Cdc28/Clb2-3XHA com-
plexes were purified as previously described [21].
Mapping of Cdc5 Phosphorylation Sites
Cells containing a 3XHA-tagged copy of Cdc5 under the control of
the endogenous promoter were grown overnight at 30ºC to OD600
0.5 overnight and then arrested in mitosis by incubating in YPD +
30 mg/ml benomyl for 2 hr. The cells were pelleted, resuspended in
50 mM HEPES-KOH [pH 7.6], transferred to a 50 ml tube, pelleted
again, and frozen in liquid nitrogen. Cells were lysed by grinding
with a mortar and pestle under liquid nitrogen. 10 g of cell powder
was resuspended in 20 ml of lysis buffer (50 mM HEPES-KOH [pH
7.6], 1 M KCl, 50 mM b-glycerophosphate, 50 mM NaF, 1 mM
EGTA, 1 mM MgCl2, 0.25% Tween-20, 5% glycerol, 1 mM PMSF).
The extract was then centrifuged for 5 min at 10,000 3 g, followed
by 100,000 3 g for 45 min. The clarified extract was incubated
with 500 mg affinity-purified anti-HA antibody coupled to 500 ml pro-
tein A agarose for 2 hr at 4ºC. The beads were then pelleted and
washed 23 with 15 ml of lysis buffer and transferred to a column.
The column was washed with 5 ml of lysis buffer before eluting
Cdc5-3XHA in 50 mM HEPES-KOH (pH 7.6), 200 mM KCl, 1 mM
EGTA, 1 mM MgCl2, 10% glycerol, supplemented with 0.5 mg/ml
HA dipeptide. The elution was TCA precipitated and run on a 10%
polyacrylamide gel. The Cdc5-3XHA band was excised and the pro-
tein was in-gel reduced, alkylated, and digested with trypsin [22].
The peptide mixture was analyzed by nanoscale-microcapillary re-
versed phase liquid chromatography tandem mass spectrometry
(LC-MS/MS) [23] by a Finnigan LTQ linear quadrupole ion trap, or a
Finnigan LTQ FT linear quadrupole ion trap/Fourier transform ion cy-
clotron resonance mass spectrometer (Thermo Electron). MS/MS
spectra were searched against the Cdc5 protein sequence with
the SEQUEST search algorithm, applying no constraints regarding
enzyme specificity and allowing serine, threonine, and tyrosine res-
idues to be phosphorylated [24]. Assignments of MS/MS spectra to
tryptic phosphopeptides were validated manually with special con-
sideration of fragment ions formed through neutral loss of phospho-
ric acid [25]. The mapping was carried out twice on two indepen-
dently isolated samples, with equivalent results.
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